u/two_mil_or_one

Correction to my own post above — I said 5mg and I have been on 7.5mg since the spring. Same argument, wrong number.

I would not generalise from one bad month to a rule. The rest of your process sounds fine.

Stopped for financial reasons and regained most of it. Not a moral story, just a budget and a documented outcome.

sulphur burps are the signature complaint and they are not dangerous

Are you comparing against phase 3 numbers for something else? They are not comparable.

small trial, big effect, wide error bars

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.

Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

the TRIUMPH programme is still running, so anything definitive is premature

What did system suitability look like on that sequence?

Purity methods differ by compound class. A gradient and wavelength developed for one peptide will not necessarily resolve the relevant impurities of another.

Genuine question — is the appetite effect still there, or is it just the scale that has paused?

Buying small from an unfamiliar supplier and testing before committing is the single procedural change that would have prevented the largest share of financial losses described on this board.

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

a lot of the confident posting here is extrapolation

money lost to a shop with nothing on file is the recurring story

What did week 31 look like compared with this one? The month either side is the useful comparison.

214nm sees the peptide bond, 280nm sees the aromatics

The system suitability argument, since it comes up whenever somebody posts a number without one.

Before the sample result means anything, the instrument has to be shown to be fit that day: replicate injections with an acceptable RSD on area, a tailing factor inside limits, adequate plate count, and a resolution check between the pair you care about.

None of that is exotic and all of it is routine in a laboratory that reports for a living. Its absence does not mean a number is wrong; it means the number is unanchored, and unanchored numbers should not be quoted to two decimal places on this board.

the scale is the least sensitive instrument you own

Disagree with this specific line. A pause at 0.25mg is not evidence that 0.25mg has stopped working.

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

This is the whole methodological point of the board in one line.

freya_baptista is right — the integration choice is a decision and it should be stated alongside the result.

I would not blame the sample yet. Everything you have described is consistent with the column rather than the vial.

Correction: that name covers two different molecules and the thread has been discussing both as one.

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

system suitability before you believe any number on the run

Adding one practical thing — run the blank. It answers this before anyone has to argue about it.

axis labels or the trace is decoration

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

Pen or vial? The step sizes available differ and it changes this answer.

Correct, and worth adding: the trial average is an average. Half the people in it did worse than 15% and were still on the drug.

Ran a blank after a high-concentration injection and found the carryover I had been calling an impurity.

That method was developed for a different compound class and would not resolve the impurities you are asking about.

ask which lines are actually stocked rather than made to order

Ordered under a name that turned out to cover two different molecules. Nobody’s fault but mine for not asking.

ask what the reference standard was

Not convinced. You are attributing a week of early fullness to the glucagon arm when the escalation rate alone would explain it.